Indication
Aucatzyl is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory (r/r) B cell precursor acute lymphoblastic leukaemia (B ALL).
Loading your page…
Loading your page…
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Marketing Authorisation Holder: Autolus GmbH
EMA Authorisation: 17/07/2025
INN: obecabtagene autoleucel
AI Drug & Interaction Analysis
Free account required
Ask Osler about Aucatzyl: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.